Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature (Q30942279)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

27 June 2017

Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature (English)

1 reference

Europe PubMed Central

27 June 2017

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Georg A Bjarnason

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Bishoy Khalil

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

John M Hudson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ross Williams

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mostafa Atri

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alex Kiss

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter N Burns

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2015

1 reference

Europe PubMed Central

27 June 2017

Urologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

171-178

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Improved flow measurement using microbubble contrast agents and disruption-replenishment: clinical application to tumour monitoring

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Sunitinib rechallenge in metastatic renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Hypertension as a predictive factor of Sunitinib activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.03.003

7 January 2021

Identifiers

10.1016/J.UROLONC.2015.03.003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25934535%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30942279&oldid=1643591803"